Athira Pharma, Inc. Logo

Athira Pharma, Inc.

Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.

ATHA | US

Overview

Corporate Details

ISIN(s):
US04746L1044
LEI:
Country:
United States of America
Address:
18706 NORTH CREEK PARKWAY, SUITE 104, 98011 BOTHELL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small-molecule therapies to restore neuronal health and slow neurodegeneration. The company's proprietary platform creates novel compounds designed to modulate the HGF (Hepatocyte Growth Factor) signaling system, a naturally occurring repair mechanism, to promote neuro-regeneration and provide neuroprotection. Athira's pipeline is aimed at treating a range of neurodegenerative diseases, including Alzheimer's and Parkinson's disease dementia. The company advances its product candidates through clinical trials to evaluate their safety and efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Athira Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Athira Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Athira Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America
SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America
SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan
4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark
SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America
SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060

Talk to a Data Expert

Have a question? We'll get back to you promptly.